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Abstract
Despite major advances in our understanding of the initiating factors that trigger many
neurodegenerative disorders, to date, no novel disease-modifying therapies have been shown to
provide significant benefit for patients who suffer from these devastating disorders. As most
neurodegenerative disorders are late-onset, slowly progressive, and appear to have long relatively
asymptomatic prodromal phases, it is possible that therapies optimally targeting the triggers of
these disorders may have limited benefit when treatment is initiated in the symptomatic patient.
Such therapies may work in the prodromal phase, or when given prophylactically, but in the
symptomatic patient there simply may be too much damage to the neuronal networks to restore
functionality by reducing or even eliminating the primary stressor. As functional neuronal demise
and overt neuronal death are almost certainly the key factors that mediate the functional
impairment, it is clear that preventing neuronal death and dysfunction will have a huge clinical
benefit. Unfortunately, we lack a detailed understanding of neuronal death pathways in almost all
neurodegenerative disorders. To rationally develop new disease modifying therapies that target
steps in the degenerative cascade downstream of the disease trigger will require a number of
factors. First, we need to refocus our basic research efforts on identifying the precise steps in the
pathological cascade that lead to neuronal death in each neurodegenerative disease and, if possible,
determine the relative placement of those events within a potentially very complex cascade.
Second, we will need to determine which of these steps are potentially targetable. Finally, we will
need to develop novel therapies that interfere with these steps and demonstrate that such
therapies alone, or in combination with therapies that target the trigger of these devastating
diseases, have clinical benefit.
Introduction
Over the last two decades there has been enormous
progress with respect to understanding the initiating fac-
tors that trigger complex cascades that ultimately result in
various neurodegenerative disorders [1-3]. Much of this
progress has been the result of 1) biochemical and histo-
chemical characterization of proteins that accumulate
within various inclusions in the diseased brain and 2)
genetic linkage studies identifying mutations in genes that
cause neurodegenerative disease. These biochemical, his-
tochemical, and genetic studies were often mutually rein-
forcing; the protein found to accumulate in the brain
proved often to be the same protein encoded by the dis-
ease causing mutant gene (see Table 1). Once mutant
genes have been identified, animal models that recapitu-
late at least some aspects of the human disease have been
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made by creating transgenic mice expressing the mutant
genes in the brain [4,5]. As there are no naturally occur-
ring animal models for many neurodegenerative diseases,
the creation of animal and cell based models based on
mutant genes identified in humans have had a tremen-
dous impact on target identification, enabled pre-clinical
studies of novel therapies in those animal models, and led
to the clinical testing of a number of novel therapeutics.
Indeed, the advent of animal models that recapitulate fea-
tures of Alzheimer' disease (AD), Parkinson's disease
(PD), Huntington's disease (HD), familial amyotrophic
lateral sclerosis (ALS), and host of other human neurode-
generative diseases, has catalyzed efforts to develop thera-
pies aimed at modifying the underlying disease process
and, to some degree, redirected the field from developing
symptomatic therapies to these potential disease-modify-
ing therapies.
Despite this progress in identifying the trigger of many
neurodegenerative diseases there have been only limited
advances with respect to the clinical treatment of patients
who suffer from these devastating and, for the most part,
lethal diseases. To date, these advances have stemmed not
from understanding the trigger of the disease, but largely
from understanding the neurochemical and functional
circuitry deficits present. For example the development of
cholinesterase inhibitors for the treatment of AD was
largely based on the observation that in AD cholinergic
neurons are severely depleted and cholinesterase and
choline acetyl transferase activity are markedly reduced
compared to controls. Indeed the neurochemical deficits
that have been reported are striking, with reductions of up
to 90% activity in AChE and CHAT in postmortem brains
of AD patients [6-8]. Similarly, the development of levo-
dopa therapy was based on the reduction in dopamine
levels in the basal ganglia [9-11]. Indeed, it is well estab-
lished that gross motor impairments are not present in
most patients with Parkinson's disease until > 70–80% of
the dopaminergic neurons in the substantia nigra have
degenerated or died, with accompanying loss of the
dopaminergic input from the nigra to the striatum.
Notably, these symptomatic therapies appear to have lit-
tle, if any, disease-modifying effect; though symptoms
may be improved, the inevitable progression of the dis-
ease is not altered to any great extent. Obviously, a therapy
that provides some symptomatic relief is better than no
therapy at all, which is what is available for almost all of
the uncommon neurodegenerative conditions. However,
ideally, we would like to do better and not only improve
symptoms but markedly slow or halt the progression of
neurodegeneration.
The natural history of typical neurodegenerative diseases 
and prophylactic therapy
Based on the study of patients with genetic forms of com-
mon and uncommon neurodegenerative diseases it can be
inferred that the majority of these diseases feature a fairly
long disease free period in which no pathological or clin-
ical changes are noted. Subsequently, there appears to be
a prodromal phase where the initiating pathology is
detectable, but the patient remains symptom free. This
prodromal phase may last for years or even decades. Dur-
ing this phase additional pathological changes occur in
Table 1: Examples of the Relationship Between Lesions, Proteins and Causal Genes in Neurodegenerative Diseases
Disease Lesions Major Protein In Deposit Genetic Alterations
Alzheimer's Plaques
NFT
Aβ
tau
Mutations/Multiplication in APP and 
Presenilin genes cause altered Aβ 
production
Parkinson's (classic)1 Lewy Body α-synuclein Mutation/Multiplication of α-synuclein 
gene
FTDP-17tau NFT tau Mutations in tau
FTLDu Ubiquitin positive inclusions TDP-43 Mutations in Granulin gene, evidence 
that Granulin interacts with TDP-43
Polyglutamine Diseases 
(e.g. Huntington's, SCA)
Inclusions of expanded Poly Q 
protein
PolyQ encoding protein Expanded CAG repeats encoded 
stretches of Poly Q
ALS Ubiquitin positive inclusions TDP-43 Mutations in TDP-43
ALS Ubiquitin positive inclusions Inclusions are TDP negative Mutations in SOD1
1 Numerous genes have now been implicated in Parkinsonism, some of these genes result in classic Lewy body pathology others do not, and some 
such as LRRK2 can produce distinct pathologies even within a single family.Molecular Neurodegeneration 2009, 4:8 http://www.molecularneurodegeneration.com/content/4/1/8
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the brain, including neuronal loss, dystrophy, and synap-
tic dysfunction. Thus, when symptoms become apparent
there is typically extensive damage to either vulnerable
brain regions in diseases that are characterized by more
focal dysfunction or widespread damage to multiple brain
regions. Indeed, given compensatory mechanisms, neuro-
nal reserve, and the relatively insensitive tests used for
clinical diagnosis of most neurodegenerative conditions,
by the time a patient presents with symptoms there is
extensive neuronal loss and dystrophy. Such a natural
progression is characteristic of Alzheimer's disease (Figure
1), where brain atrophy can be seen even in patients with
mild-cognitive impairment of the AD type, a well-recog-
nized prodromal phase of AD. Notably, if they come to
autopsy, patients with MCI of the AD type also exhibit
extensive AD neuropathology, and cross-sectional study
of postmortem brains from patients with Trisomy 21 indi-
cate that these individuals will become demented long
after they show the initial signs of AD pathology, namely
accumulation of amyloid beta protein (Aβ) in plaques
and tau in neurofibrillary tangles. Although difficult to
prove definitively, one can infer, based on the imaging
studies, that one can lose up to 80% of their dopaminergic
neurons in the substantia nigra before showing overt
motor deficits [12,13]. Indeed, the latter example suggests
that symptoms may result from the additional loss or dys-
function of relatively few surviving neurons, whereas the
massive loss of neurons in the prodromal disease phase
did not result in overt clinical symptoms.
If massive neuronal loss or massive neuronal dysfunction
occurs before overt symptoms, and there is a long delay
between initiating pathology and the clinical symptoms,
it is only reasonable to question the potential "therapeu-
tic" effectiveness of treatments targeting the trigger of the
disease. In contrast, it is reasonable to propose that such
treatments would be highly effective, if initiated prior to
onset of the primary pathology or during the early phases
of that pathology prior to significant neuronal loss. The
problem with such a scenario is that it may take decades
to prove that a given therapy works, and given the finan-
cial, regulatory, and ethical obstacles to such true preven-
tion trials, there is no current road map that suggests such
prevention trials will become feasible in the near future.
Progression of a typical Neurodegenerative Disease Figure 1
Progression of a typical Neurodegenerative Disease. Alzheimer's disease is used as an example to exhibit the natural 
progression of a neurodegenerative disease. In the top panel typical magnetic resonance imaging (MRI) scans are shown from a 
cognitively intact "normal" subject (left), a subject with mild cognitive impairment of the Alzheimer's type (middle), and a 
patient with AD (right). Note that even the subject with MCI despite displaying minimal symptoms has already clearly lost brain 
mass and that this increases as the disease progresses. Indeed there is a clear cascade effect in which underlying pathology 
drives neuronal loss and degeneration leading to clinical symptoms. Based on this one would argue that the optimal time to tar-
get the "trigger" of AD would be prior to any signs of damage to the brain or during the initial prodromal phase when patho-
logical changes might be apparent but no clinical signs are yet apparent. Another therapeutic opportunity would be to try to 
stop the neuronal loss downstream of the initiating pathology.Molecular Neurodegeneration 2009, 4:8 http://www.molecularneurodegeneration.com/content/4/1/8
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Thus, investigators who study neurodegenerative diseases
and are serious about translating an enhanced under-
standing of pathogenesis of these diseases into therapies
face a very challenging paradox: most therapies developed
as potentially disease modifying target the trigger of the
disease; yet they will be tested in the therapeutic setting
where it is not unreasonable to think they will be ineffec-
tive or minimally effective. There simply has been too
much downstream damage to the brain.
Pathogenic cascades downstream of disease triggers
Despite the progress in understanding the triggers of neu-
rodegenerative disease, the precise pathways that lead to
neuronal death are not well established. Indeed, for
almost every neurodegenerative disease multiple hypoth-
eses exist regarding the mechanism or mechanisms that
lead to neuronal dysfunction. In many cases, common
pathways are invoked across multiple diseases. Indeed,
inflammation, oxidative stress, mitochondrial dysfunc-
tion, and axonal transport deficits are postulated to play
some role in almost every neurodegenerative disorder
[14-18]. Likewise, proteasomal dysfunction, chronic
stress responses, altered autophagy, calcium dyshomeos-
tasis, and neuronal cell cycle induction also appear to be
common, if not universal features, of many neurodegen-
erative diseases [19-25]. However, placing these pathways
in the proper relationship to the disease trigger is chal-
lenging.
From a completely conceptual point of view, one can
think of the pathological cascades initiated by a given
neurodegenerative disease trigger in three different
generic scenarios (Figure 2). The first scenario is a com-
pletely linear cascade in which the initial toxic insult leads
to a linear cascade that eventually results in neuronal
death. The second scenario would be a branching cascade
where the toxic insult simultaneously initiates multiple
pathological cascades that then collectively contribute to
neuronal death and dysfunction. The third scenario is a
Different types of Neurodegenerative Cascades Figure 2
Different types of Neurodegenerative Cascades. The utility of targeting events downstream of any disease trigger will in 
part be determined by the type of cascade that is established. If a linear cascade (left panel) is established there may be many 
events that can be targeted that will have equal efficacy. Halting any step in the cascade may stop the cascade. In a branching 
cascade (middle panel), the situation where a single initiating event triggers multiple insults that then mutually contribute to 
neuronal death, the efficacy of targeting a single downstream pathway may be much more limited. In the case of a mixed cas-
cade (right panel), in which an initiating event can trigger a complex cascade which may initially be linear and then later branch, 
understanding the placement of any given insult within cascade may be critical with respect to determining how effective ther-
apies targeting that step will be with respect to slowing or halting neurodegeneration.
Linear Cascade Branching Cascade Mixed Cascade
Trigger
1q Insult
Neuronal Death/Dysfunction
2q Insult
3q Insult
4q Insult
Trigger
Insult A Insult B Insult C Insult D
Neuronal Death/Dysfunction
Trigger
1q Insult
2q Insult A 2q Insult B 2q Insult C
Neuronal Death/DysfunctionMolecular Neurodegeneration 2009, 4:8 http://www.molecularneurodegeneration.com/content/4/1/8
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mixed cascade where both linear and branching cascades
might be initiated in various orders by the trigger.
The distinctions between these types of cascades are not
trivial. From an investigational point of view, it has
proven extremely challenging to precisely order the events
in the cascade even in animal models that show massive
neuronal loss, such as mutant tau models of FTDP-17
[26]. From a therapeutic point of view distinguishing
between these cascades will almost certainly guide deci-
sions regarding therapies that target factors downstream
of the trigger. For example, if neuronal death is mediated
by a linear cascade, the likelihood that a therapeutic agent
targeting any one of the insults within that cascade will
have a major effect is much larger. This is especially true if
the therapeutic agent is targeting an early insult in the cas-
cade. If neuronal death is mediated by a branching cas-
cade, a therapy targeting any single downstream pathway
may have limited efficacy. In any case, given that in most
neurodegenerative diseases a mixture of linear and
branching cascades are likely to play a role in neuronal
death, enhanced efforts to understand the order of events
would seem to be critical in order to efficiently guide opti-
mal therapies.
How do we dissect the downstream cascades?
Even with advances in imaging the human brain and
development of probes for certain molecular phenotypes
(e.g. amyloid imaging agents to visualize amyloid load in
AD), it is unlikely that study of the progression of human
neurodegenerative disease will be sufficient to dissect the
downstream cascades leading to neuronal death. Like-
wise, cell culture models of neurodegenerative disease
may provide hypotheses regarding the primacy of various
pathways, but such hypotheses eventually will need to be
tested in animal models. Indeed, animal models of neuro-
degenerative disease are essential to developing novel
therapies and understanding the role of various factors in
driving neuronal death and dystrophy. However, one
must be cautious about "therapeutic" studies in animal
models. In many cases the studies are not therapeutic but
actually reflect primary prevention. The treatment was ini-
tiated prior to the onset of detectable pathology. In other
cases, such as many APP mouse models of Aβ deposition,
the mutant human transgene expression in the brain does
not fully recapitulate the human disease, especially the
extent and degree of neuronal loss. In such cases one has
to question whether a treatment that shows efficacy in the
mouse model with no neuronal loss will be effective in a
human with massive neuronal loss.
Should the field refocus on the mediators of cell death and 
therapies targeting those pathways?
There is a sharp dichotomy within the neurodegenerative
disease field between common diseases such as AD and
PD and the plethora of rare neurodegenerative disease
such as the polyglutamine disorders, with respect to com-
mercial interest in developing novel therapies. For the
common neurodegenerative conditions, there is tremen-
dous incentive to develop new therapies. There is a huge
unmet medical need, a huge market, and a new AD or PD
therapy even of modest efficacy will be a blockbuster in
terms of sales. In contrast, the relatively small number of
patients with any individual rare neurodegenerative dis-
eases means that there is much less commercial interest in
developing new therapies. Thus, most therapeutic devel-
opment for these conditions occurs in academic laborato-
ries with an increasing effort from philanthropic
organizations to assist with the clinical development.
Occasionally, biotech companies or major pharmaceuti-
cal companies will partner in these efforts, but typically
with limited resources.
If one considers the recent therapeutic developments in
AD as an example of the prioritization of therapeutic
development in a common neurodegenerative disease,
one can see that pharmaceutical companies have largely
invested in two main strategies. Targeting the trigger,
namely efforts to prevent, remove, or neutralize accumu-
lation and aggregation of toxic Aβ; and, more recently, a
renewed interest in cognitive-enhancing agents. There is
very limited development of novel strategies intervening
downstream of the trigger, largely because there is not a
good "road map" for what to target. Yet, based on ration-
ale outlined above, therapies targeting downstream trig-
gers could have a major impact on disease progression.
With the downsizing of basic research efforts within the
commercial sector, it is highly likely that most novel tar-
gets downstream of the trigger will be identified in the
non-profit sector. However, again using AD as an exam-
ple, much of the funding portfolio for basic AD research
is invested in factors that influence the trigger, and a much
smaller segment of the portfolio is focused on those
downstream pathways. As one could argue, at least with
respect to anti-Aβ therapies, that the numbers of therapeu-
tic approaches are sufficient to determine whether such
strategies will be efficacious in humans with AD, it would
seem that there should be a renewed focus by academics
with respect to identifying the downstream pathways that
mediate neuronal death. Such studies will almost cer-
tainly identify novel targets that then can be moved
towards the clinic.
In contrast to diseases where there is a clear commercial
incentive for therapeutic development (e.g. AD and PD),
the non-profit sector must play a larger role in therapeutic
development for the uncommon neurodegenerative dis-
eases. One possible way to leverage such therapeutic
development is to demonstrate that the pathway targetedMolecular Neurodegeneration 2009, 4:8 http://www.molecularneurodegeneration.com/content/4/1/8
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may actually play a role not only in the rare condition but
in a common condition such as PD or AD. Obviously, this
is unlikely to work for therapies targeting a trigger of the
disease, but could work if dysfunction of a critical down-
stream pathway drives neuronal dysfunction and death in
multiple diseases.
Summary
In this review series, a panel of experts in the neurodegen-
erative disease field will address the questions of "What
kills neurons in neurodegenerative disease?" In the vast
majority of cases, we simply don't know the detailed
answer. We do know the trigger, or at least in most dis-
eases there is a reasonable consensus that we know
enough about the trigger to develop strategies to target it
therapeutically (Appendix 1). It is the intent of this series
to provide a "road map" for the field to refocus on the
question of the pathways that conspire to kill neurons in
various neurodegenerative diseases, and hopefully galva-
nize a new era of therapeutic development that will result
in novel disease modifying therapies for patients suffering
form these devastating disorders (Appendix 2).
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Appendix 1
Key observations
￿ Through genetic, pathological, biochemical, and animal
modeling studies the triggers of many neurodegenerative
disease have been identified.
￿ Most neurodegenerative diseases are late-onset, slowly
progressive, and appear to have long relatively asympto-
matic prodromal phase.
￿ Clinical symptoms are typically apparent only after
extensive pathological damage including extensive neuro-
nal dystrophy and degeneration.
￿ The cascades downstream of the initiating triggers of dis-
ease that lead to neuronal death and dysfunction remain
enigmatic for most neurodegenerative diseases.
￿ Therapies targeting the triggers of neurodegenerative dis-
eases are likely to have the greatest benefit if given during
the prodromal phase or earlier.
￿ Therapies that prevent neuronal death and dystrophy by
targeting steps in the cascade downstream of the disease
trigger may provide disease modification even in patients
with clinical symptoms.
Appendix 2
Critical next steps
￿ Intensify efforts to indentify the pathways that lead to
neurodegeneration.
￿ Not only identify the individual steps within the neuro-
degenerative cascade, but also correctly order the steps
within the cascade.
￿ If animal models do not fully recapitulate neurodegen-
erative disease phenotypes continue to develop better ani-
mal models.
￿ Develop safe therapies that are designed to block down-
stream events in neurodegenerative disease cascades and
prevent neuronal dysfunction and degeneration in pre-
clinical studies.
￿ Test these therapies in the clinic.
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